Atyr Pharma Stock News

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological p

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually.

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences in March.

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, which is being held February 14 – 17, 2022, at the Marriott Marquis in New York, NY.

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path

aTyr Pharma <> said the U.S. Adopted Names ((USAN)) Council and the World Health Organizations ((WHO)) International Nonproprietary Name ((INN)) expert committee have selected

Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022

SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the United States Adopted Names (USAN) Council and the World Health Organization''s (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923, a novel immunomodulator targeting neuropilin-2 (NRP2), in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease. "aTyr is working to develop a new class of medicines based on extracellular tRNA synthetase biology, and the assignment of the nonproprietary name efzofitimod for ATYR1923 is an important step as we continue to advance this potentially disease-modifying immunomodulator to its next stage of development," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Efzofitimod is engineered from a naturally occurring splice variant of histidyl-tRNA synthetase, which is enriched in lung tissue and we believe plays a role in the natural regulation of the immune system.

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ: LIFE ), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, ATYR1923, for the treatment of sarcoidosis. ATYR1923 is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states. Clinical proof-of-concept was recently established for ATYR1923 in a Phase 1b/2a study in patients with pulmonary sarcoidosis, the main form of the disease, and the company expects to initiate a registrational trial in this indication this year. The FDA''s Office of Orphan Drug Products grants orphan status to support the development of medicines for patients with unmet needs for rare disorders affecting fewer than 200,000 people in the United States.